Worthing Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Narat, Santosh
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
Person, Contact
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
Moore, Sally
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
Stewart, Grant D
WIRE, NCT03741426: - Novel Treatments in Renal Cell Cancer

Recruiting
2
60
Europe
Olaparib, AZD2281, KU-0059436, LYNPARZA, Cediranib, AZD2171, Durvalumab, MEDI4736
CCTU- Cancer Theme, University of Cambridge, AstraZeneca, Cancer Research UK
Renal Cell Cancer
11/25
11/25
NCT03756597: PAN-study: Pan-Cancer Early Detection Study (PAN)

Completed
N/A
268
Europe
ReCIVA, CASPER
Owlstone Ltd, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK
Gastric Cancer, Esophageal Cancer, Liver Cancer
12/22
07/23
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Active, not recruiting
N/A
280
Europe, Canada, US
GAG score
Elypta
Clear Cell Renal Cell Carcinoma
05/25
12/25
Wilson, Jamie
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
Coldwell, Sue
No trials found
Hodgson, Luke
No trials found
Whitehouse, Pauline
No trials found
Chadburn, Indra
No trials found
Yates, Edward
No trials found
Maddocks, Matthew
No trials found

Download Options